Abstract
This study is a head-to-head comparison between temsirolimus and an antiangiogenic agent as first-line treatment for advanced clear-cell renal cell carcinoma patients with clinical characteristics of poor prognosis. Efficacy was modest with both therapies, suggesting that their frontline use in unselected patients should be discouraged.
Original language | English (US) |
---|---|
Pages (from-to) | 687-694 |
Number of pages | 8 |
Journal | European Urology Oncology |
Volume | 3 |
Issue number | 5 |
DOIs | |
State | Published - Oct 2020 |
Keywords
- Cytokines and angiogenic factors
- First line
- International Metastatic Renal Cell Carcinoma Database Consortium risk groups
- Pazopanib
- Poor-risk metastatic renal cell carcinoma
- Temsirolimus
ASJC Scopus subject areas
- Surgery
- Oncology
- Radiology Nuclear Medicine and imaging
- Urology
MD Anderson CCSG core facilities
- Biostatistics Resource Group